Literature DB >> 26086871

Genetic association between VEGF polymorphisms and BRONJ in the Korean population.

H Choi1, J H Lee2, H J Kim, W Park, J-H Lee1, J-H Kim1.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the association between vascular endothelial growth factor (VEGF) polymorphisms and bisphosphonate-related osteonecrosis of the jaw (BRONJ) in the Korean population. SUBJECTS AND METHODS: Forty-five individuals (2 men, 43 women; mean age: 68.7 ± 12.3 years) were recruited for this study. All visited the Yonsei University Dental Hospital for surgical intervention from January 2012 to January 2013 and had a history of bisphosphonate (BP) administration (oral and/or intravenous). Patients were allocated to case (n = 26) or control (n = 19) groups according to the patients' selection criteria. Association between three VEGF single nucleotide polymorphisms (rs699947 (-2578 C>A), rs2010963 (-634 G>C) and rs3025039 (+936 C>T)) and BRONJ were investigated using multiple logistic regression analysis and Fisher's exact test where appropriate (α = 0.05).
RESULTS: The CC homozygotes of rs2010963 and rs3025039 of VEGF gene were associated with an increased risk of BRONJ (P = 0.04, 0.03, respectively). In haplotype analysis, no differences in haplotype C-C (-2578/-634) and haplotype C-C-C (-2578/-634/+936) were observed.
CONCLUSION: The CC homozygotes of rs2010963 and rs3025039 polymorphisms in the VEGF gene were associated with an increased risk of BRONJ in the Korean population. Further epidemiological cohort studies with a larger sample size would be required to confirm the suggestive correlations.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bisphosphonate; bisphosphonate-related osteonecrosis of the jaw; gene polymorphisms; vascular endothelial growth factor

Mesh:

Substances:

Year:  2015        PMID: 26086871     DOI: 10.1111/odi.12355

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  4 in total

1.  Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer.

Authors:  Catherine Van Poznak; Evan L Reynolds; Cherry L Estilo; Mimi Hu; Bryan Paul Schneider; Daniel L Hertz; Christina Gersch; Jacklyn Thibert; Dafydd Thomas; Mousumi Banerjee; James M Rae; Daniel F Hayes
Journal:  Oral Dis       Date:  2020-12-14       Impact factor: 3.511

Review 2.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

3.  Identifying genetic variants underlying medication-induced osteonecrosis of the jaw in cancer and osteoporosis: a case control study.

Authors:  Kye Hwa Lee; Su-Hwan Kim; Chang Hyen Kim; Byung Joo Min; Grace Juyun Kim; Younggyun Lim; Hun-Sung Kim; Kang-Min Ahn; Ju Han Kim
Journal:  J Transl Med       Date:  2019-11-20       Impact factor: 5.531

4.  Local delivery of hydrogel encapsulated vascular endothelial growth factor for the prevention of medication-related osteonecrosis of the jaw.

Authors:  Dileep Sharma; Stephen Hamlet; Cedryck Vaquette; Eugen Bogdan Petcu; Poornima Ramamurthy; Saso Ivanovski
Journal:  Sci Rep       Date:  2021-12-03       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.